Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vupanorsen in Familial Partial Lipodystrophy
NCT03514420Phase 2Completed
- Sponsor
- Akcea Therapeutics
- Start
- Jun 2018
- Primary completion
- Jul 2019
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of vupanorsen in familial partial lipodystrophy (FPLD), sponsored by Akcea Therapeutics. Started Jun 2018; status: completed.
02
Drugs
vupanorsen
03
Conditions
familial partial lipodystrophy (FPLD)
Beyond the preview
Go deeper on NCT03514420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03514420.